Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:ESLA NASDAQ:GOVX NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$5.65-1.1%$7.57$5.29▼$112.85$3.50M0.87170,193 shs12,672 shsESLAEstrella Immunopharma$1.05-2.8%$0.91$0.63▼$1.78$38.92M0.37103,212 shs22,977 shsGOVXGeoVax Labs$0.70-5.5%$0.72$0.43▼$3.94$11.11M3.57975,079 shs1.02 million shsSNYRSynergy CHC$2.32-0.9%$3.23$1.30▼$10.00$21.90MN/A444,139 shs53,003 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+0.35%+4.39%-18.19%-50.35%+570,999,900.00%ESLAEstrella Immunopharma0.00%+12.50%+27.81%+1.40%+3.85%GOVXGeoVax Labs-1.10%-0.81%+1.26%-34.06%-80.77%SNYRSynergy CHC-2.90%+10.38%-34.64%+11.43%+2,240.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$5.65-1.1%$7.57$5.29▼$112.85$3.50M0.87170,193 shs12,672 shsESLAEstrella Immunopharma$1.05-2.8%$0.91$0.63▼$1.78$38.92M0.37103,212 shs22,977 shsGOVXGeoVax Labs$0.70-5.5%$0.72$0.43▼$3.94$11.11M3.57975,079 shs1.02 million shsSNYRSynergy CHC$2.32-0.9%$3.23$1.30▼$10.00$21.90MN/A444,139 shs53,003 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+0.35%+4.39%-18.19%-50.35%+570,999,900.00%ESLAEstrella Immunopharma0.00%+12.50%+27.81%+1.40%+3.85%GOVXGeoVax Labs-1.10%-0.81%+1.26%-34.06%-80.77%SNYRSynergy CHC-2.90%+10.38%-34.64%+11.43%+2,240.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AESLAEstrella Immunopharma 3.00Buy$16.001,423.81% UpsideGOVXGeoVax Labs 3.00Buy$8.501,118.29% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00331.03% UpsideCurrent Analyst Ratings BreakdownLatest GOVX, ESLA, BDRX, and SNYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/7/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/29/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/17/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K7.45N/AN/A$2.91 per share1.94ESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AN/AGOVXGeoVax Labs$3.95M2.81N/AN/A$0.48 per share1.45SNYRSynergy CHC$34.83M0.63$0.26 per share9.06($1.91) per share-1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/A-$0.26N/A∞N/AN/A-1,132.38%-358.54%9/26/2025 (Estimated)GOVXGeoVax Labs-$24.99M-$2.01N/AN/AN/A-403.88%-408.80%-279.89%11/11/2025 (Estimated)SNYRSynergy CHC$2.12M$0.386.113.93N/A10.02%-18.56%20.28%N/ALatest GOVX, ESLA, BDRX, and SNYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million7/28/2025Q2 2025GOVXGeoVax Labs-$0.41-$0.35+$0.06-$0.35$0.37 million$0.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.011.751.75ESLAEstrella ImmunopharmaN/A0.160.16GOVXGeoVax LabsN/A2.032.03SNYRSynergy CHCN/A2.742.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%ESLAEstrella Immunopharma0.35%GOVXGeoVax Labs6.09%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%ESLAEstrella Immunopharma55.10%GOVXGeoVax Labs1.20%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals20620,000618,000Not OptionableESLAEstrella ImmunopharmaN/A37.07 million16.64 millionNot OptionableGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableSNYRSynergy CHC409.44 million4.10 millionN/AGOVX, ESLA, BDRX, and SNYR HeadlinesRecent News About These CompaniesSynergy CHC (SNYR) vs. The Competition Financial SurveySeptember 4 at 3:45 AM | americanbankingnews.comReviewing Synergy CHC (NASDAQ:SNYR) & Grove Collaborative (NYSE:GROV)August 29, 2025 | americanbankingnews.comSynergy CHC Completes $4.375M Public OfferingAugust 27, 2025 | tipranks.comSynergy CHC Corp. Announces the Closing of its $4.375 Million Public OfferingAugust 27, 2025 | globenewswire.comSynergy CHC (SNYR) & The Competition Financial ComparisonAugust 26, 2025 | americanbankingnews.comSynergy CHC 1.75M share Secondary priced at $2.50August 26, 2025 | msn.comSynergy CHC Corp. Announces Pricing of $4.375 Million Public Offering | SNYR Stock NewsAugust 25, 2025 | gurufocus.comSynergy CHC Corp. Announces Pricing of $4.375 Million Public Offering of Common StockAugust 25, 2025 | quiverquant.comQSynergy CHC Corp. Announces Pricing of $4.375 Million Public OfferingAugust 25, 2025 | globenewswire.comSynergy CHC's (NASDAQ:SNYR) Earnings Quality Is LowAugust 22, 2025 | finance.yahoo.comSynergy CHC Corp to Present at the 2025 Gateway Conference on September 4thAugust 21, 2025 | markets.businessinsider.comNew to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...August 20, 2025 | palmbeachpost.comPSynergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + EnergyAugust 18, 2025 | taiwannews.com.twTNew to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...August 18, 2025 | finanznachrichten.deSynergy CHC announces major distribution with for FOCUSfactor Focus + EnergyAugust 18, 2025 | msn.comSynergy CHC Expands FOCUSfactor Distribution with EG AmericaAugust 18, 2025 | tipranks.comSynergy CHC files to sell 1.28M shares of common stockAugust 15, 2025 | msn.comSynergy Chc EPS Jumps 86 Percent in Q2August 15, 2025 | theglobeandmail.comSynergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | finanznachrichten.deSynergy CHC reports Q2 EPS 17c vs 9c last yearAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTesla’s Pennant Just Snapped: Here’s What It Means for the StockBy Sam Quirke | August 14, 2025Tesla's Breakout: Why This Rally Looks Far From OverBy Sam Quirke | August 20, 2025Tesla Is Balanced on a Knife Edge: Time to Tread CarefullyBy Sam Quirke | August 8, 2025Tesla Just Had Its Best Day in 2 Months—Here’s What It MeansBy Sam Quirke | August 26, 2025Tesla Bulls Need to Tread Very Carefully Right NowBy Sam Quirke | September 3, 2025GOVX, ESLA, BDRX, and SNYR Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$5.65 -0.06 (-1.05%) Closing price 03:59 PM EasternExtended Trading$5.67 +0.02 (+0.42%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Estrella Immunopharma NASDAQ:ESLA$1.06 -0.02 (-1.85%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.GeoVax Labs NASDAQ:GOVX$0.70 -0.04 (-5.52%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Synergy CHC NASDAQ:SNYR$2.32 -0.02 (-0.85%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Lockheed Martin: Is the Market Overlooking This Defensive Giant? Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
